Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma

Taylor J Brueseke, Krishnansu S TewariDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine, Orange, CA, USAAbstract: Ovarian cancer is the most deadly gynecologic cancer, with 15,000 anticipated deaths within the United States alone in 2012, and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brueseke TJ, Tewari KS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/bcfd5f4d05634caeb5e25b23ffa4b700
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bcfd5f4d05634caeb5e25b23ffa4b700
record_format	dspace
spelling	oai:doaj.org-article:bcfd5f4d05634caeb5e25b23ffa4b7002021-12-02T01:47:48ZToll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma1179-1438https://doaj.org/article/bcfd5f4d05634caeb5e25b23ffa4b7002013-05-01T00:00:00Zhttp://www.dovepress.com/toll-like-receptor-8-augmentation-of-innate-immunity-in-platinum-resis-a13130https://doaj.org/toc/1179-1438Taylor J Brueseke, Krishnansu S TewariDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine, Orange, CA, USAAbstract: Ovarian cancer is the most deadly gynecologic cancer, with 15,000 anticipated deaths within the United States alone in 2012, and new treatment strategies are needed. Ovarian cancer tumors are known to host an immunosuppressive microenvironment. This suppression may be reversible via activation of the innate immune response. Toll-like receptor 8 activates innate immunity while simultaneously inhibiting the effects of regulatory T cells within the ovarian cancer tumors. VTX-2337 is a novel small molecule ligand of Toll-like receptor 8 and is currently the subject of a Phase II randomized, double-blind, placebo-controlled trial Gynecologic Oncology Group (GOG)-3003 for patients with recurrent platinum-resistant ovarian cancer. We look forward to the results of this trial as support for the paradigm of process therapy in the treatment of ovarian cancer.Keywords: immunotherapy, ovarian cancer, Gynecology Oncology Group partners, VTX 2237Brueseke TJTewari KSDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2013, Iss Supplement 1, Pp 13-19 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Brueseke TJ Tewari KS Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
description	Taylor J Brueseke, Krishnansu S TewariDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine, Orange, CA, USAAbstract: Ovarian cancer is the most deadly gynecologic cancer, with 15,000 anticipated deaths within the United States alone in 2012, and new treatment strategies are needed. Ovarian cancer tumors are known to host an immunosuppressive microenvironment. This suppression may be reversible via activation of the innate immune response. Toll-like receptor 8 activates innate immunity while simultaneously inhibiting the effects of regulatory T cells within the ovarian cancer tumors. VTX-2337 is a novel small molecule ligand of Toll-like receptor 8 and is currently the subject of a Phase II randomized, double-blind, placebo-controlled trial Gynecologic Oncology Group (GOG)-3003 for patients with recurrent platinum-resistant ovarian cancer. We look forward to the results of this trial as support for the paradigm of process therapy in the treatment of ovarian cancer.Keywords: immunotherapy, ovarian cancer, Gynecology Oncology Group partners, VTX 2237
format	article
author	Brueseke TJ Tewari KS
author_facet	Brueseke TJ Tewari KS
author_sort	Brueseke TJ
title	Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
title_short	Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
title_full	Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
title_fullStr	Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
title_full_unstemmed	Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
title_sort	toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/bcfd5f4d05634caeb5e25b23ffa4b700
work_keys_str_mv	AT brueseketj tolllikereceptor8augmentationofinnateimmunityinplatinumresistantovariancarcinoma AT tewariks tolllikereceptor8augmentationofinnateimmunityinplatinumresistantovariancarcinoma
_version_	1718402920490205184

Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma

Ejemplares similares